Leidos shares slipped 1.38% in the latest session, even as major U.S. indices registered modest gains. Trading volume rose 12% above the 30-day average, signaling elevated investor activity. Analysts attribute the underperformance to profit-taking following a 14% rally over the past three months and rotation into cyclical names. The stock’s relative weakness contrasts with the S&P 500’s 0.6% gain, suggesting investors are rebalancing ahead of the firm’s fiscal Q2 earnings release in late May.

Leidos has beaten consensus EPS estimates in seven of the last eight quarters, with an average surprise of +4.2%. Two primary factors underpin this trend: a growing $23.4 billion contract backlog—up 5% year-over-year—and disciplined operating expense management, which lifted adjusted EBITDA margins by 120 basis points in the latest fiscal year. Management’s guidance for mid‐single-digit revenue growth and a free cash flow conversion rate above 90% further supports the case for another upside surprise when results arrive.

During the past three months, Leidos secured over $2.1 billion in new awards from the U.S. Department of Defense and civilian agencies, including a follow-on intelligence support task order valued at $450 million. The defense solutions segment, representing 62% of total revenue, is poised for 6–8% annual growth driven by cybersecurity and modernization projects. The health group, contributing 18% of sales, should benefit from expanding government IT modernization budgets as well as recent wins in electronic health records integration.